Seattle's oral small molecule tyrosine kinase inhibitor tucatinib Phase 3 trial reaches primary and secondary endpoints

today, Seattle Genetics(http://announced that its HER-specific oral small molecule tyrosine kinase inhibitor tucatinib, in the treatment of HER2-positive metastatic breast cancer patients in the critical phase 3trial(http://HER2CLIMB, reached the main and critical secondary endpoints of the trialAbout Tucatinib
Tucatinib is an oral tyrosine kinase inhibitor that is highly selective for HER2, but has no significant inhibition of EGFR in the same human epidermal growth factor receptor familyPrevious studies have shown anti-cancer activity, both as a monotherapy and in combination with chemotherapy and other HER2-targeteddrug(http://Previously, the U.SFDA(http://has granted tucatinib orphan drug eligibility for the treatment of breast cancer patients with brain metastatic tumorsAbout HER2CLIMB a total of 612 patients participated in the Phase 3 clinical trial called HER2CLIMB The trial was a key clinical study in a randomized, double-blind, active control group designed to compare the efficacy and safety of tucatinib's combined standard therapeutic drugs teratozumab and capecitabine, compared to qutozumab and carpedamine, in patients with advanced local non-resection or metastatic HER2 breast cancer 　　Patients involved in the trial have been treated with hydroquation, pertuzumab and ado-trastuzumab emtansine (T-DM1), and 47% of patients with brain metastatic tumors 　　The results showed that the combination therapy added to tucatinib significantly improved the patient's progressionless life (PFS) and reduced the patient's risk of disease progression or death by 46% compared to the active control group, reaching the main endpoint of the trial 　　Progressionless life (PFS) reached one year in 33% of patients in the treatment group, compared with 12% of patients in the active control group The median PFS of the patients was 7.8 months and 5.6 months, respectively 　　Compared to the control group, triple therapy also improved the total survival (OS) of patients, reducing the risk of death by 34% Forty-five percent of patients in the treatment group had OS for 2 years, compared with 27 percent of patients in the active control group The median OS in patients was 21.9 months and 17.4 months, respectively